MedCity News March 27, 2023
Vertex Pharmaceuticals aims to CRISPR Therapeutics’ gene-editing technology to develop type 1 diabetes cell therapies that don’t prompt the immune system to reject them. This approach could compete with a Sana Biotechnology program expected to reach its first test in humans this year.
Vertex Pharmaceuticals has two clinical-stage programs for type 1 diabetes, each employing different methods for preventing the immune system from rejecting the cell therapies. For a third program in preclinical development, the drug developer wants to use gene editing to avoid rejection and it has agreed to pay CRISPR Therapeutics $100 million to apply that company’s technology to the effort.
The upfront payment announced Monday gives Boston-based Vertex non-exclusive rights to CRISPR’s gene editing technology to develop...
Today's Sponsors
Today's Sponsor